SOHO 2023 | Approaching and managing relapsed high-risk myeloma
Marc Braunstein, MD, PhD, NYU Long Island School of Medicine, New York City, NY, shares some insights into the treatment and management of relapsed high-risk multiple myeloma (MM), emphasizing the importance of enrolling patients in clinical trials and offering triplet or quadruplet therapies as a standard of care (SOC). Dr Braunstein comments on the success of second-line multi-agent combinations in randomized clinical trials, and concludes by discussing the management of patients with triple-class refractory disease, who may benefit from clinical trials evaluating the early use of CAR-T therapy or bispecific antibodies. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie: Consultant (advisory board), Adaptive Biotechnologies: Consultant (advisory board)
ADC Therapeutics: Consultant (advisory board), American College of Physicians: MSKAP Question Writer, Bristol Myers Squibb: Consultant (advisory board), Janssen: Faculty bureau, Bristol Myers Squibb: Research funding, CTI Biopharma: Consultant (advisory board), Epizyme: Consultant (advisory board), Glaxosmithkline: Consultant (advisory board), Guidepoint: Consultant, Janssen: Consultant (advisory board), Janssen: Research funding, LAVA Therapeutics: Consultant (advisory board), Pfizer: Consultant (advisory board), Pfizer/ICON: Clinical independent reviewer, Sanofi: Consultant, Seagen: Consultant (advisory board)
